On May 4, 2020, NanoViricides announced that it has signed a Confidential Disclosure Agreement with a leading pharmaceutical company in the Asian region to explore collaborating on the Company’s COVID-19 program.

The Company intends to perform testing against SARS-CoV-2 (the virus that causes COVID-19 disease) and is in advanced discussions with at least two sites that have such capability. This testing is expected to enable the Company to declare a clinical drug candidate for COVID-19 based on viral load reduction.